European Medicines Agency (2013) European public assessment report: Abilify Maintena (EMEA/H/C/002755/0000) [online; accessed 15 January 2014]

European Medicines Agency (2000) Points to consider on switching between superiority and non-inferiority [online; accessed 15 January 2014]

Kane JM, Sanchez M, Perry PP et al. (2012) Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry 73: 617–24

Kane JM, Sanchez R, Zhao J et al. (2013) Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics 16: 917–25

Khanna P, Suo T, Komossa K et al. (2014) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews Issue 1: CD006569. doi: 10.1002/14651858.CD006569.pub5.

Medicines and Healthcare products Regulatory Agency (2013) Antipsychotic drugs [online; accessed 15 January 2014]

Mortimer A (2007) Symptom rating scales and outcome in schizophrenia. The British Journal of Psychiatry 191: s7–s14

National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia in adults: treatment and management (NICE clinical guideline 178)

National Institute for Health and Clinical Excellence (2011) Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (NICE technology appraisal guidance 213)

Otsuka Pharmaceuticals (UK) Ltd (2014) Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection summary of product characteristics [online; accessed 15 January 2014]

US National Institutes of Health (2014) Identifier: NCT01795547 [online; accessed 23 January 2014]

US National Institutes of Health (2014) Identifier: NCT01129882 [online; accessed 23 January 2014]